A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants

Summary

The purpose of this study is to compare the amount of tirzepatide that gets into the blood stream and how long it takes the body to get rid of it, when given as a solution formulation via an autoinjector versus a conventional prefilled syringe. The tolerability of tirzepatide will also be evaluated and information about any adverse effects experienced will be collected. Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be about 14 weeks, including screening.

Timeline

Start

2019-08-19

Primary completion

2019-12-16

Completion

2019-12-16

Drugs

Indications

No indication recorded.